v3.22.4
ACQUISITION-RELATED CHARGES (GAINS), IMPAIRMENT AND OTHER - Impairment and Other (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Restructuring Reserve [Roll Forward]      
Severance-related expenses $ 4,494 $ 26,371 $ 0
Total acquisition-related charges 11,245 40,900 150
Changes in contingent consideration (29,476) (989) 5,204
Total acquisition-related charges (gains), impairment and other 10,903 42,911 5,166
Acquired IPR&D      
Restructuring Reserve [Roll Forward]      
Impairment of acquired IPR&D 26,134 0 0
Nuance Biotech Co. Ltd.      
Restructuring Reserve [Roll Forward]      
Gain (loss) on contract termination 0 (3,000) 0
DepoCyte      
Restructuring Reserve [Roll Forward]      
Gain (loss) on contract termination 0 0 188
Flexion      
Restructuring Reserve [Roll Forward]      
Changes in contingent consideration (18,292) 1,174 0
Myoscience Acquisition      
Restructuring Reserve [Roll Forward]      
Acquisition related fees   700 200
Changes in contingent consideration 11,200 2,200 5,200
Impairment of acquired IPR&D (11,184) (2,163) 5,204
Acquisition-related fees      
Restructuring Reserve [Roll Forward]      
Acquisition related fees 1,032 10,963 0
Other acquisition expenses      
Restructuring Reserve [Roll Forward]      
Acquisition related fees 5,719 3,566 150
Termination of license agreement      
Restructuring Reserve [Roll Forward]      
Gain (loss) on contract termination $ 3,000 $ 0 $ 0